Last reviewed · How we verify
Novarel
At a glance
| Generic name | Novarel |
|---|---|
| Sponsor | Ferring Pharmaceuticals |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Eight Weeks of Androgen Priming by hCG Before IVF/ICSI in Women With Low Ovarian Reserve (Phase 4)
- Phase III Study on the Effects of Recombinant HCG Ovulation Triggering on Stimulation, Embryonic and Pregnancy Parameters in an IVF Program (Phase 3)
- An Exploratory Study to Explore the Correlation Between the Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response Using New Gonal-f® Pen in Assisted Reproductive Technolog (N/A)
- Endometrial Advancement After Rec or u-HCG Triggering (Phase 4)
- Early Prediction Of Preterm Delivery By Measurement Of Maternal Serum Markers (N/A)
- Role of Ratio of Progesterone to Number of Follicles as a Prognostic Tool for IntracytoplasmicSperm Injection Outcome (N/A)
- Phase III Investigator and Assessor Blinded 1:1 Randomized, Parallel-group Multicenter Study to Compare Efficacy and Safety of Two r-hFSH Formulations (AFOLIA vs Gonal-f® RFF) in Normal Ovulatory Wome (Phase 3)
- PCOS and IVF: A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Novarel CI brief — competitive landscape report
- Novarel updates RSS · CI watch RSS
- Ferring Pharmaceuticals portfolio CI